<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00385138</url>
  </required_header>
  <id_info>
    <org_study_id>TMC-CAN-05-03</org_study_id>
    <nct_id>NCT00385138</nct_id>
  </id_info>
  <brief_title>Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.</brief_title>
  <acronym>Platform</acronym>
  <official_title>A Clinical Trial Comparing Treatment With Cangrelor (in Combination With Usual Care) to Usual Care, in Subjects Who Require Percutaneous Coronary Intervention (PCI).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate that the efficacy of cangrelor
      (combined with usual care) is superior to that of usual care, in subjects requiring
      percutaneous coronary intervention (PCI) as measured by a composite of all-cause mortality,
      myocardial infarction (MI), and ischemia-driven revascularization (IDR).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient evidence of the clinical effectiveness of cangrelor
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)</measure>
    <time_frame>randomization through 48 hours post randomization</time_frame>
    <description>mITT population; (composite incidence)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of All-cause Mortality or MI</measure>
    <time_frame>randomization through 48 hours post randomization</time_frame>
    <description>mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of All-cause Mortality</measure>
    <time_frame>randomization through 48 hours post randomization</time_frame>
    <description>mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MI</measure>
    <time_frame>randomization through 48 hours post randomization</time_frame>
    <description>mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of IDR</measure>
    <time_frame>randomization through 48 hours post randomization</time_frame>
    <description>mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Stent Thrombosis</measure>
    <time_frame>randomization through 48 hours post randomization</time_frame>
    <description>mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Stroke</measure>
    <time_frame>randomization through 48 hours post randomization</time_frame>
    <description>mITT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of All-cause Mortality</measure>
    <time_frame>randomization through 1 year post randomization</time_frame>
    <description>mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Procedure Events [Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, Unsuccessful Procedure, New Thrombus or Suspected Thrombus, and/or Acute Stent Thrombosis]</measure>
    <time_frame>During index PCI</time_frame>
    <description>mITT population A patient could have multiple procedural events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of GUSTO Severe / Life-threatening</measure>
    <time_frame>randomization through 48 hours post randomization</time_frame>
    <description>Major bleeding (non-CABG-related) - Safety population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major</measure>
    <time_frame>randomization through 48 hours post randomization</time_frame>
    <description>Major bleeding (non-CABG-related) - Safety population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ACUITY Major Bleeding</measure>
    <time_frame>randomization through 48 hours post randomization</time_frame>
    <description>Major bleeding (non-CABG-related) - Safety population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ACUITY Major Bleeding Without Hematoma &gt;/= 5 cm</measure>
    <time_frame>randomization through 48 hours post randomization</time_frame>
    <description>Major bleeding (non-CABG-related) - Safety population excludes ACUITY major bleeding for which the only qualifying event was hematoma &gt;/= 5 cm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of All-cause Mortality, MI, or IDR</measure>
    <time_frame>randomization through 30 days post randomization</time_frame>
    <description>mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of All-cause Mortality or MI</measure>
    <time_frame>randomization through 30 days post randomization</time_frame>
    <description>mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of All-cause Mortality</measure>
    <time_frame>randomization through 30 days post randomization</time_frame>
    <description>mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MI</measure>
    <time_frame>randomization through 30 days post randomization</time_frame>
    <description>mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of IDR</measure>
    <time_frame>randomization through 30 days post randomization</time_frame>
    <description>mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Stent Thrombosis</measure>
    <time_frame>randomization through 30 days post randomization</time_frame>
    <description>mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Stroke</measure>
    <time_frame>randomization through 30 days post randomization</time_frame>
    <description>mITT population</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5364</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Acute Coronary Syndrome (ACS)</condition>
  <arm_group>
    <arm_group_label>Cangrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cangrelor</intervention_name>
    <description>cangrelor bolus (30 mcg/kg) &amp; cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)</description>
    <arm_group_label>Cangrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>clopidogrel capsules (600 mg) at end of PCI</description>
    <arm_group_label>Cangrelor</arm_group_label>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo bolus &amp; placebo infusion</intervention_name>
    <description>placebo bolus (30 mcg/kg) &amp; placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules - end of PCI</intervention_name>
    <description>Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing</description>
    <arm_group_label>Cangrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules - end of infusion</intervention_name>
    <description>Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Angiography demonstrating atherosclerosis amenable to treatment by percutaneous coronary
        intervention (PCI) with or without stent implantation and diagnosis of Acute Coronary
        Syndrome (ACS) by elevated cardiac markers or ischemic chest discomfort w/electrocardiogram
        changes + age &gt; 65 or diabetes.

        Exclusion Criteria:

          1. Not a candidate for PCI

          2. ST-segment elevation myocardial infarction (STEMI) within 48 hours of randomization

          3. Increased bleeding risk: ischemic stroke within the last year or any previous
             hemorrhagic stroke, intra-cranial tumor, cerebral arteriovenous malformation, or
             intracranial aneurysm; recent (&lt;1 month) trauma or major surgery [including coronary
             artery bypass graft (CABG) surgery]; currently receiving warfarin, active bleeding

          4. Impaired hemostasis: known International Normalized Ratio (INR) &gt;1.5 at screening;
             past or present bleeding disorder (including congenital bleeding disorders such as von
             Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained
             clinically significant bleeding disorders), thrombocytopenia (platelet count
             &lt;100,000/ÂµL) at screening

          5. Severe hypertension not adequately controlled by antihypertensive therapy at the time
             of randomization

          6. Receipt of fibrinolytic therapy in the 12 hours preceding randomization

          7. Receipt of any thienopyridine (clopidogrel or ticlopidine) in the 7 days preceding
             randomization

          8. Glycoprotein IIb/IIIa (GPI) Inhibitor usage within the previous 12 hours [applicable
             to unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) patients]
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simona Skerjanec, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>The Medicines Company</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deepak L. Bhatt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert A. Harrington, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Innovis Health</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA; CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009 Dec 10;361(24):2330-41. doi: 10.1056/NEJMoa0908629.</citation>
    <PMID>19915222</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2006</study_first_submitted>
  <study_first_submitted_qc>October 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2006</study_first_posted>
  <results_first_submitted>April 22, 2013</results_first_submitted>
  <results_first_submitted_qc>March 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2014</results_first_posted>
  <last_update_submitted>April 18, 2014</last_update_submitted>
  <last_update_submitted_qc>April 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Percutaneous Coronary Intervention (PCI)</keyword>
  <keyword>ACS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Cangrelor</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were selected for randomization based on the need for percutaneous coronary intervention (PCI).
Randomization could only occur after the need for PCI was confirm by angiography.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cangrelor</title>
          <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
        </group>
        <group group_id="P2">
          <title>Clopidogrel</title>
          <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2695"/>
                <participants group_id="P2" count="2669"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-treat (ITT)</title>
              <participants_list>
                <participants group_id="P1" count="2693">All patients randomized excluding two (2) who withdrew consent for using study data.</participants>
                <participants group_id="P2" count="2669"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent-to-treat (mITT)</title>
              <participants_list>
                <participants group_id="P1" count="2656">Excludes 37 patients who either did not receive study drug or have PCI.</participants>
                <participants group_id="P2" count="2645">Excludes 24 patients who either did not received study drug or have PCI.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="2662">Includes all randomized patients who received at least one dose of study drug.</participants>
                <participants group_id="P2" count="2650">Includes all randomized patients who received at least one dose of study drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2665">&quot;Completed&quot; means patient completed scheduled visits or developed a primary endpoint event.</participants>
                <participants group_id="P2" count="2641">&quot;Completed&quot; means patient completed scheduled visits or developed a primary endpoint event.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>mITT population</population>
      <group_list>
        <group group_id="B1">
          <title>Cangrelor</title>
          <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
        </group>
        <group group_id="B2">
          <title>Clopidogrel</title>
          <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2656"/>
            <count group_id="B2" value="2645"/>
            <count group_id="B3" value="5301"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>mITT population</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" spread="11.4"/>
                    <measurement group_id="B2" value="62.5" spread="11.3"/>
                    <measurement group_id="B3" value="62.5" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>mITT population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="747"/>
                    <measurement group_id="B2" value="782"/>
                    <measurement group_id="B3" value="1529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1909"/>
                    <measurement group_id="B2" value="1863"/>
                    <measurement group_id="B3" value="3772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>The analysis by region was performed on the mITT population.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="815"/>
                    <measurement group_id="B2" value="809"/>
                    <measurement group_id="B3" value="1624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="403"/>
                    <measurement group_id="B2" value="394"/>
                    <measurement group_id="B3" value="797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="342"/>
                    <measurement group_id="B2" value="345"/>
                    <measurement group_id="B3" value="687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belarus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="215"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)</title>
        <description>mITT population; (composite incidence)</description>
        <time_frame>randomization through 48 hours post randomization</time_frame>
        <population>mITT population, based on available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)</title>
          <description>mITT population; (composite incidence)</description>
          <population>mITT population, based on available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2654"/>
                <count group_id="O2" value="2641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of All-cause Mortality or MI</title>
        <description>mITT population</description>
        <time_frame>randomization through 48 hours post randomization</time_frame>
        <population>mITT population, based on available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All-cause Mortality or MI</title>
          <description>mITT population</description>
          <population>mITT population, based on available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2654"/>
                <count group_id="O2" value="2641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                    <measurement group_id="O2" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of All-cause Mortality</title>
        <description>mITT population</description>
        <time_frame>randomization through 48 hours post randomization</time_frame>
        <population>mITT population, based on available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All-cause Mortality</title>
          <description>mITT population</description>
          <population>mITT population, based on available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2654"/>
                <count group_id="O2" value="2641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of MI</title>
        <description>mITT population</description>
        <time_frame>randomization through 48 hours post randomization</time_frame>
        <population>mITT population, based on available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of MI</title>
          <description>mITT population</description>
          <population>mITT population, based on available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2654"/>
                <count group_id="O2" value="2641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of IDR</title>
        <description>mITT population</description>
        <time_frame>randomization through 48 hours post randomization</time_frame>
        <population>mITT population, based on available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of IDR</title>
          <description>mITT population</description>
          <population>mITT population, based on available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2654"/>
                <count group_id="O2" value="2641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Stent Thrombosis</title>
        <description>mITT population</description>
        <time_frame>randomization through 48 hours post randomization</time_frame>
        <population>mITT population, based on available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Stent Thrombosis</title>
          <description>mITT population</description>
          <population>mITT population, based on available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2654"/>
                <count group_id="O2" value="2641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Stroke</title>
        <description>mITT</description>
        <time_frame>randomization through 48 hours post randomization</time_frame>
        <population>mITT population, based on available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Stroke</title>
          <description>mITT</description>
          <population>mITT population, based on available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2654"/>
                <count group_id="O2" value="2641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of All-cause Mortality</title>
        <description>mITT population</description>
        <time_frame>randomization through 1 year post randomization</time_frame>
        <population>mITT population, based on available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All-cause Mortality</title>
          <description>mITT population</description>
          <population>mITT population, based on available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2628"/>
                <count group_id="O2" value="2618"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Procedure Events [Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, Unsuccessful Procedure, New Thrombus or Suspected Thrombus, and/or Acute Stent Thrombosis]</title>
        <description>mITT population A patient could have multiple procedural events.</description>
        <time_frame>During index PCI</time_frame>
        <population>mITT population, based on available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Procedure Events [Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, Unsuccessful Procedure, New Thrombus or Suspected Thrombus, and/or Acute Stent Thrombosis]</title>
          <description>mITT population A patient could have multiple procedural events.</description>
          <population>mITT population, based on available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2656"/>
                <count group_id="O2" value="2645"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of GUSTO Severe / Life-threatening</title>
        <description>Major bleeding (non-CABG-related) - Safety population</description>
        <time_frame>randomization through 48 hours post randomization</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of GUSTO Severe / Life-threatening</title>
          <description>Major bleeding (non-CABG-related) - Safety population</description>
          <population>Safety population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2662"/>
                <count group_id="O2" value="2650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major</title>
        <description>Major bleeding (non-CABG-related) - Safety population</description>
        <time_frame>randomization through 48 hours post randomization</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major</title>
          <description>Major bleeding (non-CABG-related) - Safety population</description>
          <population>Safety population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2662"/>
                <count group_id="O2" value="2650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of ACUITY Major Bleeding</title>
        <description>Major bleeding (non-CABG-related) - Safety population</description>
        <time_frame>randomization through 48 hours post randomization</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of ACUITY Major Bleeding</title>
          <description>Major bleeding (non-CABG-related) - Safety population</description>
          <population>Safety population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2662"/>
                <count group_id="O2" value="2650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of ACUITY Major Bleeding Without Hematoma &gt;/= 5 cm</title>
        <description>Major bleeding (non-CABG-related) - Safety population excludes ACUITY major bleeding for which the only qualifying event was hematoma &gt;/= 5 cm.</description>
        <time_frame>randomization through 48 hours post randomization</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of ACUITY Major Bleeding Without Hematoma &gt;/= 5 cm</title>
          <description>Major bleeding (non-CABG-related) - Safety population excludes ACUITY major bleeding for which the only qualifying event was hematoma &gt;/= 5 cm.</description>
          <population>Safety population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2662"/>
                <count group_id="O2" value="2650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of All-cause Mortality, MI, or IDR</title>
        <description>mITT population</description>
        <time_frame>randomization through 30 days post randomization</time_frame>
        <population>mITT population, based on available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All-cause Mortality, MI, or IDR</title>
          <description>mITT population</description>
          <population>mITT population, based on available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2647"/>
                <count group_id="O2" value="2629"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of All-cause Mortality or MI</title>
        <description>mITT population</description>
        <time_frame>randomization through 30 days post randomization</time_frame>
        <population>mITT population, based on available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All-cause Mortality or MI</title>
          <description>mITT population</description>
          <population>mITT population, based on available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2647"/>
                <count group_id="O2" value="2629"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                    <measurement group_id="O2" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of All-cause Mortality</title>
        <description>mITT population</description>
        <time_frame>randomization through 30 days post randomization</time_frame>
        <population>mITT population, based on available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All-cause Mortality</title>
          <description>mITT population</description>
          <population>mITT population, based on available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2647"/>
                <count group_id="O2" value="2629"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of MI</title>
        <description>mITT population</description>
        <time_frame>randomization through 30 days post randomization</time_frame>
        <population>mITT population, based on available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of MI</title>
          <description>mITT population</description>
          <population>mITT population, based on available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2647"/>
                <count group_id="O2" value="2629"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189"/>
                    <measurement group_id="O2" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of IDR</title>
        <description>mITT population</description>
        <time_frame>randomization through 30 days post randomization</time_frame>
        <population>mITT population, based on available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of IDR</title>
          <description>mITT population</description>
          <population>mITT population, based on available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2647"/>
                <count group_id="O2" value="2629"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Stent Thrombosis</title>
        <description>mITT population</description>
        <time_frame>randomization through 30 days post randomization</time_frame>
        <population>mITT population, based on available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Stent Thrombosis</title>
          <description>mITT population</description>
          <population>mITT population, based on available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2647"/>
                <count group_id="O2" value="2629"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Stroke</title>
        <description>mITT population</description>
        <time_frame>randomization through 30 days post randomization</time_frame>
        <population>mITT population, based on available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor</title>
            <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Stroke</title>
          <description>mITT population</description>
          <population>mITT population, based on available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2647"/>
                <count group_id="O2" value="2629"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected through 48 hours after study drug initiation</time_frame>
      <desc>The analysis population used for adverse event reporting is the Safety Population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cangrelor</title>
          <description>cangrelor bolus (30 mcg/kg) &amp; infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion</description>
        </group>
        <group group_id="E2">
          <title>Clopidogrel</title>
          <description>placebo bolus &amp; infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>coronary artery perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>coronary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>electromechanical dissociation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>myocardial rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>torsade de pointes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>anticoagulation drug level below therapeutic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>cardiac enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>myelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>angioneurotic oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="596" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="530" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="2650"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="2662"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="2650"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI communications regarding trial results are prohibited until after the communication and publication of the multi-center results by Sponsor, but no more than 12 months after conclusion of the trial at all sites.
PI must submit results communications to sponsor for review at least 40 days prior to submission for publication and Sponsor may embargo such communications for a period that is less than or equal to 135 days solely to seek appropriate patent protection.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Discontinued per prespecified stopping rules after the 70% interim analyses was conducted indicating the trial was not likely not meet the goal of demonstrating superiority to clopidogrel administered as usual care. No safety issues were identified.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Meredith Todd</name_or_title>
      <organization>The Medicines Company</organization>
      <phone>973.290.6088</phone>
      <email>meredith.todd@themedco.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

